Regenesome Tech Forum 2026 Held: Reporting Business Progress and Longevity Research Strategy
Space Seed Holdings and Regenesome hosted the 'Regenesome Tech Forum 2026' on April 23, 2026. The event featured updates on business progress and the unveiling of a new research strategy focused on brain-targeted nanoparticle studies and AI-driven R&D efficiency.
📋 Article Processing Timeline
- 📰 Published: May 26, 2026 at 06:40
- 🔍 Collected: May 25, 2026 at 22:01
- 🤖 AI Analyzed: May 25, 2026 at 22:05 (3 min after Collected)
## Regenesome Tech Forum 2026 Held: Reporting Business Progress and Longevity Research Strategy
Space Seed Holdings Inc. (HQ: Minato-ku, Tokyo; CEO: Kengo Suzuki) and its subsidiary dedicated to the medical sector, Regenesome Inc. (HQ: Minato-ku, Tokyo; President: Zentaro Sakuma), hosted the 'Regenesome Tech Forum 2026' on April 23, 2026. At the forum, the companies reported on their business progress and research achievements, while outlining their research strategy for this fiscal year, which focuses on brain-targeted research within the longevity field, using 'nanoparticles' as a core technological approach.
In the first half of the session, Zentaro Sakuma, President of Regenesome, reported on the business development and financial status of the food brand 'Gindou.' In the second half, Kengo Suzuki, CEO of Space Seed Holdings and CEO of Regenesome, shared his vision for streamlining research and development by utilizing AI, building upon the research accomplishments accumulated thus far. Additionally, external guests were invited to engage in discussions on the forefront of neurotechnology and brain science.
### The Relationship Between the Brain and Nanoparticles
The brain is equipped with a robust defense mechanism called the 'blood-brain barrier (BBB)' that prevents the entry of harmful substances. This barrier is the greatest obstacle to the delivery of many drugs and functional ingredients to the brain. Nanoparticles can carry active ingredients to target tissues while protecting them from decomposition through precise control of particle size and surface design. Research into this approach is advancing globally as a potent method for crossing the BBB and controlling distribution within the brain. In brain-focused longevity research, how to deliver ingredients to the brain is considered just as critically important as finding effective ingredients, and nanoparticle design is believed to hold the key.
### Guest Speakers
Three guests who support Regenesome's research and business activities participated in the forum:
- **Taisuke Ichihara**, Future Co-creation Lab, Healthcare Innovation Division, Japan System Techniques Co., Ltd. (JAST)
As an independent IT company listed on the Prime Market of the Tokyo Stock Exchange, JAST specializes in medical big data. A partner that has long supported Regenesome, the company shared its vision for advancing the business by leveraging its medical data covering approximately 10 million people and its years of systems development expertise.
- **Takahiro Adachi**, Associate Professor, Institute of Medical Science, Tokyo University of Science (TUS), Department of Mibyo Control
Specializing in B-cell signaling, intestinal immunity, and bio-imaging, Professor Adachi provided insights into longevity research based on his knowledge connecting food, immunity, and 'Mibyo' (the state of being between health and illness).
- **Shinnosuke Mizuno**, CNTO, FastNeura Inc.
Leading the overall management and joint research for 'Sync,' a cognitive expansion system from a company that integrates neurotechnology and AI. Currently a student at the University of Tokyo Faculty of Medicine, Mizuno discussed the technologies for approaching the brain and the possibilities of AI application from the dual perspective of neurophysiological research (presented at domestic conferences) and AI/LLM research.
### Forum Overview
- **Name:** Regenesome Tech Forum 2026
- **Date/Time:** April 23, 2026 (Thu), 17:00–19:00
- **Venue:** TAKANAWA GATEWAY Link Scholars' Hub (LiSH) Studio1/Lab
- **Organizers:** Regenesome Inc. / Space Seed Holdings Inc.
### Company Profiles
**Regenesome Inc.**
- Business: R&D in the longevity sector. Research and social implementation of drug delivery technologies, including food-derived nanoparticles.
- Representative: Zentaro Sakuma
- Website: https://regenesome.com/
**Space Seed Holdings Inc.**
- Founded: January 2024
- Business: Space utilization research and other deep tech-related businesses.
- Representative: Kengo Suzuki
- Website: https://ss-hd.co.jp/
Space Seed Holdings Inc. (HQ: Minato-ku, Tokyo; CEO: Kengo Suzuki) and its subsidiary dedicated to the medical sector, Regenesome Inc. (HQ: Minato-ku, Tokyo; President: Zentaro Sakuma), hosted the 'Regenesome Tech Forum 2026' on April 23, 2026. At the forum, the companies reported on their business progress and research achievements, while outlining their research strategy for this fiscal year, which focuses on brain-targeted research within the longevity field, using 'nanoparticles' as a core technological approach.
In the first half of the session, Zentaro Sakuma, President of Regenesome, reported on the business development and financial status of the food brand 'Gindou.' In the second half, Kengo Suzuki, CEO of Space Seed Holdings and CEO of Regenesome, shared his vision for streamlining research and development by utilizing AI, building upon the research accomplishments accumulated thus far. Additionally, external guests were invited to engage in discussions on the forefront of neurotechnology and brain science.
### The Relationship Between the Brain and Nanoparticles
The brain is equipped with a robust defense mechanism called the 'blood-brain barrier (BBB)' that prevents the entry of harmful substances. This barrier is the greatest obstacle to the delivery of many drugs and functional ingredients to the brain. Nanoparticles can carry active ingredients to target tissues while protecting them from decomposition through precise control of particle size and surface design. Research into this approach is advancing globally as a potent method for crossing the BBB and controlling distribution within the brain. In brain-focused longevity research, how to deliver ingredients to the brain is considered just as critically important as finding effective ingredients, and nanoparticle design is believed to hold the key.
### Guest Speakers
Three guests who support Regenesome's research and business activities participated in the forum:
- **Taisuke Ichihara**, Future Co-creation Lab, Healthcare Innovation Division, Japan System Techniques Co., Ltd. (JAST)
As an independent IT company listed on the Prime Market of the Tokyo Stock Exchange, JAST specializes in medical big data. A partner that has long supported Regenesome, the company shared its vision for advancing the business by leveraging its medical data covering approximately 10 million people and its years of systems development expertise.
- **Takahiro Adachi**, Associate Professor, Institute of Medical Science, Tokyo University of Science (TUS), Department of Mibyo Control
Specializing in B-cell signaling, intestinal immunity, and bio-imaging, Professor Adachi provided insights into longevity research based on his knowledge connecting food, immunity, and 'Mibyo' (the state of being between health and illness).
- **Shinnosuke Mizuno**, CNTO, FastNeura Inc.
Leading the overall management and joint research for 'Sync,' a cognitive expansion system from a company that integrates neurotechnology and AI. Currently a student at the University of Tokyo Faculty of Medicine, Mizuno discussed the technologies for approaching the brain and the possibilities of AI application from the dual perspective of neurophysiological research (presented at domestic conferences) and AI/LLM research.
### Forum Overview
- **Name:** Regenesome Tech Forum 2026
- **Date/Time:** April 23, 2026 (Thu), 17:00–19:00
- **Venue:** TAKANAWA GATEWAY Link Scholars' Hub (LiSH) Studio1/Lab
- **Organizers:** Regenesome Inc. / Space Seed Holdings Inc.
### Company Profiles
**Regenesome Inc.**
- Business: R&D in the longevity sector. Research and social implementation of drug delivery technologies, including food-derived nanoparticles.
- Representative: Zentaro Sakuma
- Website: https://regenesome.com/
**Space Seed Holdings Inc.**
- Founded: January 2024
- Business: Space utilization research and other deep tech-related businesses.
- Representative: Kengo Suzuki
- Website: https://ss-hd.co.jp/
FAQ
リジェネソームテックフォーラム2026の目的は何ですか？
これまでの事業進捗と研究成果の報告、および今年度のロンジェビティ（健康長寿）研究戦略として「脳」と「ナノ粒子」を軸とした方針を示すことを目的としています。
ロンジェビティ研究においてナノ粒子が重要な理由は何ですか？
脳には血液脳関門（BBB）という防御機構があり薬剤の到達を阻むため、精密設計されたナノ粒子を用いることで有効成分を分解から守り、標的組織である脳へ確実に届けることが可能になるからです。
今年度の研究戦略における技術的方針は？
「脳」を対象領域に据え、「ナノ粒子」を技術の軸として活用します。さらにAIを活用して研究開発をいっそう効率化していく構想を掲げています。
フォーラムにはどのようなゲストが登壇しましたか？
日本システム技術株式会社の市原泰介氏（医療ビッグデータ）、東京科学大学の安達貴弘准教授（未病制御学）、株式会社FastNeuraの水野晋之介氏（ニューロテクノロジー・AI）の3名が登壇しました。
スペースシードホールディングスとリジェネソームの役割分担は？
スペースシードホールディングスは深層技術関連事業を統括し、子会社のリジェネソームはロンジェビティ領域における研究開発および食品由来ナノ粒子等の社会実装を担っています。